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Abstract
Background: Treatment-resistant depression (TRD) is a serious and relatively common clinical condition. Lack of
consensus on defining and staging TRD remains one of the main barriers to understanding TRD and approaches to
intervention. The Maudsley Staging Method (MSM) is the first multidimensional model developed to define and stage
treatment-resistance in “unipolar depression”. The model is being used increasingly in treatment and epidemiological
studies of TRD and has the potential to support consensus. Yet, standardised methods for rating the MSM have not
been described adequately. The aim of this report is to present standardised approaches for rating or completing the
MSM.
Method: Based on the initial development of the MSM and a narrative review of the literature, the developers of the
MSM provide explicit guidance on how the three dimensions of the MSM–treatment failure, severity of depressive
episode and duration of depressive episode– may be rated.
Result: The core dimension of the MSM, treatment failure, may be assessed using the Maudsley Treatment Inventory
(MTI), a new method developed for the purposes of completing the MSM. The MTI consists of a relatively comprehensive
list of medications with options for rating doses and provisions treatment for multiple episodes. The second dimension,
severity of symptoms, may be assessed using simple instruments such as the Clinical Global Impression, the Psychiatric
Status Rating or checklist from a standard diagnostic checklist. The standardisation also provides a simple rating scale for
scoring the third dimension, duration of depressive episode.
Conclusion: The approaches provided should have clinical and research utility in staging TRD. However, in proposing this
model, we are fully cognisant that until the pathophysiology of depression is better understood, staging methods can
only be tentative approximations. Future developments should attempt to incorporate other biological/
pathophysiological dimensions for staging.
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Background
Treatment-resistance is a common clinical phenomenon
in medicine. In chronic conditions like epilepsy, multiple
sclerosis and hypertension, at least 30% of patients fail
to respond adequately (attain remission of symptoms) to
their first medication [1–3]. Ten to 15% tend to suffer
chronically. Although depressive disorders may have a
more favourable prognosis compared with primary
psychotic disorders such as schizophrenia [4, 5], never-
theless 20%–40% of patients treated fail to respond to
their first treatment with antidepressants [6] and up to
15% to multiple antidepressants [7].
The history of treatment-resistance in depression is as
old as the history of antidepressant treatments itself.
Soon after the introduction of imipramine [8], Robert
Kuhn conceded that “in many cases, however, there is
merely some degree of improvement, making the condi-
tion more bearable for the patient, and even permitting
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resumption of work, though at the cost of considerable
effort. In other cases there is no effect at all” [8]. Kuhn’s
observation was confirmed and quantified within few
years, in two key studies, one from the United Kingdom
(UK) and another from the United States (US). The US
study compared the efficacy of imipramine or isocarbox-
azid and phenelzine against electroconvulsive therapy
[9]. Overall, poor treatment response was observed in
50% of those receiving medication. The proportion for
ECT was lower (25%) while that for isocarboxazid was
the highest (66.7%). In a multi-centre study of the
Medical Research Council (MRC) in the UK, involving
269 inpatients, 16% of those receiving ECT, 28% on
imipramine and 62% on phenelezine failed to show
improvement [10]. When a more strict definition of im-
provement was applied as having no or only “slight
symptoms”, the rate failing to show improvement in-
creased to 27% for ECT, 48% for imipramine and 70%
for phenelezine. In 1974, the WHO convened a confer-
ence on TRD and attempted to define the concept,
which led to a series of related publications [11–14].
Nearly 50 years later, despite the development of rela-
tively diverse treatment options, and better understand-
ing of optimisation strategies, at least 30% of people
with depression do not show satisfactory improvement
[15]. Thus treatment-resistance has remained a relatively
common occurrence since the beginning of the psycho-
pharmacology of depression and continues to be part of
day to day clinical practice.
When treatment-resistance develops, the burden to pa-
tients comes not just from distressing symptoms and the
associated disability but also from the treatment. Those
who become treatment resistant often receive regimens
combining two or more different medications, with poten-
tial longer-term side effect burden. Although it is difficult
to disentangle the adverse effects on physical health of
depression from that of medication use, there are sugges-
tions that long-term use of moderate doses of antidepres-
sants has been associated with the development of
diabetes [16] and ischaemic heart disease [17, 18]. Also, as
exemplified in depression, patients with treatment-
resistant conditions are likely to suffer from co-morbid
physical and mental disorders, to experience marked and
protracted functional impairment, and to incur signifi-
cantly higher healthcare costs [19–22]. All this underscore
the public health relevance of TRD and the need for
focused research into its aetiology, epidemiology and
treatment. Although the first essential step to conduct
such a research is to have a consensus in defining what
constitutes treatment-resistance and to establish appropri-
ate methods for staging its severity, so far there is no con-
sensual definition or staging for treatment-resistance [23].
At the heart of the challenge in defining and staging TRD
remains the lack of external validator or biological and
physiological marker of depressive disorders and response
to treatment. These markers will transform our ap-
proaches to staging treatment-resistance. Until then, help-
ful approaches to staging, including multi-dimensional
models are being developed.
The Maudsley staging method
To support the effort to better understand and stage TRD,
we developed a multidimensional staging model, the
Maudsley Staging Method (MSM) [24]. The initial
development of the model was based on extensive litera-
ture review, and systematic assessment of the dimensions
making the MSM as well as testing of the construct using
original data. The MSM has shown promising predictive
validity for both short-term [24–26] and longer-term out-
comes [27, 28] of TRD. In addition to indications of con-
struct validity based on more elaborate evaluation [29],
the MSM has also been used for screening purposes in
clinical trials [30, 31] and in studies of determinants of
treatment outcomes [32].
The tool was developed as a loosely structured instru-
ment such that a clinician with mental health training
would be able to complete it. However, we have not pub-
lished a detailed guidance on how the MSM should be
completed. We have received many requests by re-
searchers to provide such guidance to help standardise
the completion of the MSM. The primary aim of this
paper is to offer tools for standardisation of the MSM.
The paper also provides context by providing an over-
view of the definitions and staging methods of
treatment-resistance in depression and by providing an
overview of the main staging methods to date.
Methods
The methods were guided by three questions relevant to
the objectives of the study: (1) How is TRD defined and
what are the staging methods for TRD employed in cli-
nical practice and research? (2) Are there any approaches
or standardised methods being used to complete the sta-
ging strategies? (3) What are the recommended outcomes
targets of treatment and how are these measured? We re-
lied on three complementary approaches to answer these
questions. (1) Methods used in the initial development of
the MSM; (2) narrative review of the literature review; (3)
review of treatment guidelines, such as the American Psy-
chiatric Association’s practice guideline for the treatment
of depression [33]; the British Association for Psycho-
pharmacology guideline for the treatment of depression
[34]; the Maudsley Prescribing Guideline [35]; and the de-
pression treatment guideline of the World Federation of
Societies of Biological Psychiatry [23, 36].
Narrative review was chosen because of the need to
focus on high level answers to the questions raised above
given the relatively broad nature of the questions asked.
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We were also convinced that a broad range of papers of
sufficient quality would be obtained through this
method. Nevertheless, we borrow some approaches from
systematic review methodology to make sure all key
works in the field of research are captured and minimise
risk of bias. Thus, we searched in Embase, Medline and
PsycInfo databases using key terms relevant for treat-
ment resistant depression and staging developed in
Pubmed. The search terms were depressive disorder,
treatment-resistant or treatment-resistant depressive dis-
order combined using the Boolean ‘AND’ operator with
staging methods. The reviewed literature was imported
into Endnote software.
Ethical considerations
Not applicable.
Results
We begin by describing the definitions and staging of
TRD and then provide specific tools for completing
or rating the MSM. These tools include measures of
the MSM dimensions, illness severity and remission,
duration of illness and treatment. We provide a new
instrument to collect data on the treatments offered
during the course of illness, the Maudsley Treatment
Inventory (MTI).
Definitions
Definitions from treatment studies
A review of 47 treatment trials explored the definitions
and staging criteria in TRD [37]. Lack of consensus was
described in both the definition of the depressive syn-
drome and in how treatment response was operationa-
lised. The depressive syndrome was defined either using
rating scales (for example, the Hamilton Rating Scale for
Depression (HRSD) [38]) or a standard operationalized
diagnostic system, such as the Diagnostic and Statistical
Manual of Mental Disorders (DSM) [39]. The required
number of antidepressant failure to define treatment
non-response was failure of at least one antidepressant
medication in about a quarter of studies, while about
half required non-response to at least two antidepressant
medications [37]. Treatment non-response was charac-
terized either in terms of failure to achieve a specified
percentage reduction in the score of a rating scale or the
continuation of a major depressive episode despite
treatment. Most studies defined treatment failure only in
relation to the presenting episode while few also
included treatment failures, or recurrences whilst on
treatment, in previous episodes. Commonly used terms
for TRD included “difficult to treat” depression, “refrac-
tory” depression, “therapy-resistant” depression and “in-
tractable” depression.
Definitions from treatment guidelines and staging methods
Several agencies have attempted to define treatment-
resistance either directly or indirectly (Table 1). The
British Association for Psychopharmacology (BAP) high-
lights that the definitions of treatment resistance vary
and concludes that “most described it as a failure to re-
spond to two or more adequate antidepressant treatment
trials”. The authors acknowledge important problems
with the definition that “arise in defining what comprises
an adequate treatment trial, which drugs are to be
included and in taking account of psychological treat-
ments” [40]. The National Institute of Clinical Excel-
lence (NICE) defined treatment-resistance in a similar
way as failure to respond to two or more sequentially
given antidepressant medications [41].
The European Agency for the Evaluation of Medicinal
Products [42]—EMEA—comments that “a patient is
considered therapy resistant when consecutive treatment
with two products of different classes, used for sufficient
length of time at an adequate dose, fail to induce an ac-
ceptable effect”. It further notes that the treatment “end
point should be relevant to this patient group, e.g., re-
mission may be more important than mean change in a
scale.” It specifies the 17-item HRSD, the Montgomery
Åsberg Depression Rating Scale, and the Clinical Global
Impression scale as acceptable scales for use to deter-
mine symptomatic improvement.
The American Psychiatric Association (APA) [33] re-
fers to “failure to respond” to treatment and interprets
this to mean failure of exhibiting at least a moderate
level of improvement following 4–8 weeks of pharmaco-
therapy or psychotherapy. It also specifies that following
any change of treatment regimen, lack of improvement
in the symptoms of major depressive disorder after an
additional treatment period of 6–8 weeks would consti-
tute failure of response. Unlike the definitions above, the
APA definition implies that failure of one medication
might be adequate to define treatment-resistance. This is
more explicit in another related definition that uses the
term “treatment-refractory”. “Refractory depression is
defined as an episode of major depression, not secondary
to a medical or drug-induced condition, which fails to
respond (or to maintain a response) to an adequate trial
of an antidepressant drug of established efficacy. An
adequate trial is defined as 6 weeks of treatment with
antidepressant at dosage considered therapeutic.” [43].
In the widely used staging method of TRD, the Thase
and Rush model [44], failure to respond to a single
adequately given antidepressant medication is implicitly
indicated to constitute TRD [44]. Recent evidence indi-
cates that failure of the first antidepressant treatment
may be the gateway towards subsequent treatment
failures, especially when the failure was not due to medi-
cation intolerance [15]. Similarly, the MSM, and a more
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recent multi-dimensional staging method (The Dutch
Measure for quantification of Treatment Resistance in
Depression (DM-TRD)) [45] specify failure of an ad-
equately given antidepressant medication to be the core
feature of TRD. The Medicare Evidence Development
and Coverage Advisory Committee met in April 2016
but did not provide an explicit definition of what the
threshold for TRD should be [46]. However, some
participants of the meeting proposed that two failed
medications or failure of an eight session psychotherapy
would constitute a TRD [47].
Current staging methods of TRD
Six staging methods were identified. The Thase and Rush
model (TRM) [44] is the most widely used model. TRM of-
fers a hierarchical model of staging [48] in which medica-
tions used at the higher order of treatment resistance are
implicitly assumed to have superior efficacy. Despite the
limited observational evidence, the TRM, by virtue of its
hierarchical nature, implies that MAOIs may be of benefit
in inducing and maintaining remission in TRD [27]. The
hierarchical assumptions and limited flexibility to accom-
modate the potentially numerous medications that may be
used to treat a resistant episode are the major drawbacks
of the TRM. The hierarchical model also assumes that
medication would be given in a certain sequence, progres-
sing from relatively safe medication to the use of
medications with potentially more serious side effects and
culminating in the use of electroconvulsive therapy (ECT).
However, in clinical practice, treatment is prescribed in an
individualised way with informed negotiation rather than
in a predetermined sequence in which ECT is the treat-
ment of last resort. Furthermore, in current practice, much
more stringent criteria [41, 49, 50] favour the use of ECT
in life threatening emergencies. As discussed above, despite
some suggestive reports [51] and the historical assump-
tions, there is also no robust evidence supporting the su-
periority of switching to a different antidepressant class as
opposed to switching within class [15, 19, 52], as implied
in the model. Neither are there clear provisions in the
model for combination or augmentation strategies [19].
In the Massachusetts General Hospital staging method
(MGH-S) [19], the staging of treatment resistance is
mainly based on the number of antidepressant medica-
tions used. A special weight is given for failure of treat-
ment with ECT, which receives a score equivalent to
three antidepressant failures. There is some limited
evidence on the utility of this model [53]. The model al-
lows flexibility to incorporate as many failed treatment
attempts as required; however, given the potential for a
large number of treatment options available currently,
the system may be less efficient and less discriminating.
Thus data obtained may not inform intervention stra-
tegies or enhance understanding and communication.
Table 1 The main definitions of treatment-resistance in depression
Year Source Definition Remarks
1974 WHO Failure of 150 mg of imipramine or equivalent
given for 4 weeks
Specifies dose and duration
Also specifies relative and absolute resistance based on dose of
imipramine (150 mg being the threshold for absolute resistance)
1997 Thase &
Rush
Failure of 1 adequately given antidepressant
medication
Primarily for staging; Assumes hierarchy
1999 Sourey et al Failure of 2 antidepressant medications from
different classes
Also called the European method; failure of 1 antidepressant medication
defined as non-response; uses chronicity criteria for staging
2002 EMEA Failure of 2 medications from different classes Suggests remission as outcome criteria
2000/
2005
APA Failure of 1 adequately given antidepressant
medication given for 4–8 weeks
Not attempt to define directly but implicit reference can be interpreted
2003 MGH Failure of 1 antidepressant medication? Primarily staging method
2007 NICE Failure of 2 antidepressant medication from
different classes
2008 BAP Failure of 2 antidepressant medication from
different classes
Refers to commonly used definitions instead of attempting to provide
a definition of its own
2009 MSM Failure of 1 adequately given antidepressant
medication
Failure to achieve remission suggested as main outcome criteria;
Primarily for staging
2015 DM-TRD Failure of 1 adequately given antidepressant
medication
Based on the MSM
2017 Conway et al Failure of 2 adequate dose-duration
antidepressants or psychotherapy from different
classes
Antidepressants given in current episode. Combinations count
individually
Abbreviations: APA = American Psychiatric Association; BAP=British Association of Psychopharmacology; DM-TRD = The Dutch Measure for quantification of Treat-
ment Resistance in Depression (DM-TRD); EMEA = The European Agency for the Evaluation of Medicinal Products; MGH =Massachusetts General Hospital (staging
method); MSM =Maudsley Staging Method; NICE = National Institute for Health and Clinical Excellence; WHO=World Health Organisation
(References provided in main text)
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There is also no clear evidence supporting the magni-
tude of the special weight given to treatment with ECT.
A third method, which is sometimes called the
European method of staging relies on matching treat-
ment resistance to specific class of medication used and
duration of treatment trials [54]. The model distin-
guishes treatment non-response from treatment-resist-
ance. The former is when there is lack of response to
one adequately used antidepressant medication; the lat-
ter is applied when two antidepressants fail. Based on
the duration and intensity of treatment trial, this method
classifies treatment-resistance into acute (TRD of less
than 12 months) and chronic TRD. The acute subtype of
TRD has five hierarchical categories. The first category,
TRD 1, is assumed when medication trial of 12–16 weeks
fails. The hierarchy is then built in what appears to be
an ad hoc fashion, in which intervals of 4–36 weeks trial
period divides the subsequent hierarchies or levels.
Chronic resistant depression is diagnosed when patient
fails to respond to several antidepressant medications in
a treatment trial period that has lasted at least
12 months. Although the recognition of chronicity in
this model is relevant, the cut off duration for chronicity
(12 months) is not in line with previous recommenda-
tions [55] and diagnostic systems [39]. The model is also
limited in scope, and its assumption regarding the diffe-
rential effectiveness of antidepressant medications does
not have clear supporting evidence.
A staging model based on depression subtypes on a
dimension of severity (psychotic, melancholic and
non-melancholic) [56] has been shown in a cross-
sectional assessment to have convergent validity with
clinician impression of resistance [56]. This model is
parsimonious, which also makes it of narrower scope.
Given the nature of the severity specifiers, this sta-
ging method may tap into bipolarity related treatment
failure, which does not always represent true treat-
ment failure.
In addition to what has been discussed above, the key
shortcoming of these staging models is their reliance on a
single criterion, mainly treatment response [44]. Although
failure of antidepressant medication to induce improve-
ment is the sine qua non of treatment-resistance, basing
staging methods solely on medication use to the exclusion
of other relevant factors such as duration and severity of
illness, type of depression and the role of psychosocial
stressors has been criticised [57].
Considering these shortcomings in the available
methods, two multi-dimensional scales have been deve-
loped [24, 45]. The Maudsley Staging Method (MSM),
was developed by the authors of this paper. Its utility in
predicting short- and medium-term outcome was also
confirmed [24, 27, 28]. Although far inferior to an
aetiological model, the MSM has improved potential
compared with the traditional linear models of staging
(Fig 1). The Dutch Measure for quantification of
Treatment Resistance in Depression (DM-TRD) [45].
This method was developed from the MSM and extends
the MSM by adding items for functional impairment,
comorbid anxiety, personality disorders and psychosocial
stressors. The DM-TRD also adds items for failed psy-
chotherapy. The authors evaluate the inter−/intra-rater
reliability and report ‘excellent’ reliability and good pre-
dictive validity.
The Maudsley staging method: Considerations in
developing the method
Definition of treatment-resistance
The MSM defines treatment-resistance as: failure to
attain significant level of improvement (equated with
clinical remission) from an accurately defined depressive
episode following treatment with an antidepressant
medication given at an adequate (minimum effective)
dose for a minimum of six weeks. Given the role of the
failure of the initial treatment as a gateway for
treatment-resistance, the MSM uses failure of the first
Fig. 1 Current linear staging models (first figure) compare with the
Maudsley staging method (last figure) and a more ideal interactive
aetiological model (middle figure)
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antidepressant treatment to designate the onset of treat-
ment- resistance. Resistance is not an all-or-nothing
phenomenon. It exists as a continuum and various factors
(dimensions) contribute to its occurrence and mainten-
ance. Three dimensions are considered (Tables 2 and 3).
The first and the core dimension is treatment failure. The
MSM incorporates severity (dimension 2) and duration of
the depressive episode (dimension 3) as important dimen-
sions to quantify treatment-resistance. These dimensions
are expanded upon below because understanding the as-
sumptions of the MSM are important for understanding
and using the proposed rating approaches.
Dimension 1-treatment failure
Failure of the first treatment appears important in that
once the first treatment trial fails, the response rate to
each successive treatment declines [15]. This implies that
failure of the first treatment is a meaningful starting point
in the measure of this conceptual continuum. There is
dearth of robust evidence supporting the superiority of
employing switching compared with augmentation stra-
tegies [3, 15] as well as the type of treatment used [44, 53],
while number of treatments sequentially failing to produce
improvement seem indicative of increasing treatment-
resistance [53, 56] and thus form the basis of the MSM
staging criterion (Table 2).
It is proposed that antidepressant treatment should
only count if treatment was given for six weeks.
However, it can rightly be argued that four weeks could
be a useful time frame given the need for early detection
of TRD and evidence from earlier treatment trials and
indications from guidelines [33, 58]. This is reflected in
the instrument to assess treatment history, the Maudsley
Treatment Inventory (MTI) (Additional file 1), which
also includes rating for a four week treatment trial to aid
further research into this question. Augmentation
strategies [35, 59] and eight sessions of ECT [60]are also
rated.
Failure of treatment is equated with failure to
achieve clinical remission. Clinical remission is gener-
ally a heterogeneous phenomenon. The two main
questions regarding the definition of remission relate
to the threshold of improvement and duration of this
improvement that would be required to designate the
clinical state as remission. Establishing the threshold
of improvement in treatment studies has relied on a
serial assessment using depression rating scales, often
the HRSD. The typical consensus based scores that
indicate remission, for example score of 7 or less in
the HRSD [61], do not often represent return to
complete wellness [62–66]. The level of impairment
or difficulty not only depends on the score but also
on the type of symptoms that are still unresolved
[66]. Thus, defining clinical remission may require
scales, such as the LIFE-chart [67] that establish re-
mission more explicitly. For the purposes of the
MSM, we have used mainly the LIFE-chart method.
However, until more validated methods or scoring
systems are developed, using the available rating
systems is unavoidable. We do not advocate using
functioning as a measure of treatment success for the
MSM even though functioning has been advocated as
an ideal treatment goal [68]. Functioning is difficult
to measure and is affected by various contextual fac-
tors. In terms of duration threshold, the definition of
remission has also relied on the assessment instru-
ment used, which varies from 1 week for the HRSD
to 1 month in some PSR ratings. For the purposes of
the MSM, a clinical definition of remission requires a
single measure over the time frame of the instrument
being used for the assessment (usually 1 to 4 weeks).
More stringent definition, as that within the DSM of
two months in remission can be used where sustained
remission is the chosen clinical outcome of interest.
Severity of depression
Inclusion of severity of depression as a staging criterion
not only makes clinical sense, but severity of illness has
also been consistently associated with non-response in nu-
merous treatment [69–72] and follow-up studies [73–77].
Severity of symptoms is the best predictor of persistence
of depressive symptoms [78] and occurrence of residual
symptoms and relapse [79, 80]. The association of severity
of illness with outcome has been demonstrated for both
severity determined by diagnosis according to specified
criterion [81, 82] or measured by dimensional scales, such
as the HRS-D [73].
Table 2 Treatment dimension of the Maudsley Staging Method
& suggested scoring conventions
Treatment Categories Scores
Treatment failures
Antidepressants Level 1: 1–2 medications 1
Level 2: 3–4 medications 2
Level 3: 5–6 medications 3
Level 4: 7–10 medications 4
Level 5: > 10 medications 5
Augmentation
Not used 0
Used 1
ECT
Not used 0
Used 1
Total maximum – (7)
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The MSM was developed using the severity categories
of the Mental and Behavioral Disorders section of the
10th revision of the International Classification of Dis-
eases (ICD-10) [83]. Despite some uncertainties as to
whether depression with psychotic symptoms may be a
distinct disorder [84–86], we have included it as the
most severe form of depression as is presented in both
ICD-10 and DSM-IV. It is worth noting that the
principle has continued in the new edition of the DSM,
DSM-5 [87]. Utility of including subsyndromal severity
level is demonstrated by the association of this level of
depression with disability [88], poor quality of life [89]
and relapse [88, 90]. Other approaches for estimating se-
verity may be used (Table 4) but require further work.
Although it is clear now that the current cut-off points
for remission based on standard rating scales, such as
the HRSD, do not correlate very well with functional re-
covery and satisfaction [63, 64, 66, 91], lower scores may
not be pragmatic targets.
Chronicity
Studies have consistently demonstrated that the longer the
duration of illness, the poorer the response to treatment in
the acute phase of [81, 82, 92, 93] or augmentation [94]
and predicted shorter relapse free survival [79, 95]. We
based our model on the duration of the presenting depres-
sive episode, irrespective of treatment experience. We clas-
sified duration into three categories. Duration of a year and
less was considered acute, between one and two years as
subacute and anything longer than two years as chronic
(Table 3). The cut-off of two years for chronic depression
was based on the criterion of the DSM-IV Text Revision
(DSM-IV-TR) diagnostic system [96].
How to complete (rate) the MSM: The MSM completion
tool
The recommendations here target research settings
where a standardised and replicable assessment is essen-
tial. This recommendation would also improve the utility
of the MSM in specialist tertiary services, where patients
with more complex needs and multiple treatment trials
and treatment failures are seen. The tool was also devel-
oped with the clinical practitioner in mind. Clinicians
can still continue to complete the MSM relatively
quickly using the usual clinical history and benefit from
the information for establishing baseline severity of
treatment resistance as well as periodic monitoring.
Rating for treatment failure (dimension 1)
We propose the use of one of three options to rate for
treatment failure: The Antidepressant Response Question-
naire (ATRQ); The Antidepressant Treatment History
Form (ATHF); or The Madusley Treatment Inventory
(MTI). The MTI is a novel approach with multiple options
for rating medication history. The MTI is described in
detail at the end of this section.
The Massachusetts General Hospital (MGH) antidepressant
treatment response questionnaire (ATRQ)
Is a self-rated instrument and defines adequate treatment
trial as treatment at adequate doses of antidepressants for
a duration of 6 weeks. The system provides operational
criteria for adequacy of dosage for each of the most com-
monly used antidepressants. The strength of the ATRQ is
the self-rated nature of the scale, which.
allows patients to indicate the level of benefit they feel
they gained from the treatment. This is important because
patients’ experience is the key outcome indicator. On the
other hand, the subjective rating may be influenced by
mood state of the person rating the instrument. Higher
scores in self-rated scores (compared with observer-rated
scales) may be reflection of personality factors [97]. Never-
theless, rating medications may be complex for patients
and is important to have additional sources of informa-
tion, such as clinical records, collateral information and
other sources.
The antidepressant treatment history form (ATHF)
Is a semi-structured tool that is used to define treatment
resistance and treatment history (for current and past
episodes), including somatic therapies [98–100]. It re-
quires detailed information from different sources about
Table 3 Illness dimensions of the Maudsley Staging Method &
suggested scoring conventions
Parameter/dimension Parameter categories Score
Duration
Acute (≤12 months) 1
Sub-acute (13–24 months) 2
Chronic (> 24 months) 3
Symptom severity
(At baseline) Subsyndromal 1
Syndromal
Mild 2
Moderate 3
Severe without
psychosis
4
Severe with psychosis 5
Highest score for illness dimensions – 8
Overall maximum score for MSM 15
Severity score categories of the
MSM
Severity range 3–15
Mild 3–6
Moderate 7–10
Severe 11–15
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the treatments and, for some medications, has provision
for adequacy based on blood levels.
The Maudsley treatment inventory (MTI)
The MTI is a semi-structured instrument that we have
developed to document psychotropic medications and
physical therapies used in the treatment of depression
and assist the completion of the MSM. The MTI was de-
veloped from existing resources, mainly the Maudsley
Prescribing Guideline [101], the BAP guideline [34] and
the APA guideline [33]. The MTI is more comprehen-
sive and potentially more suitable for rating TRD com-
pared with other schedules developed to document
treatment history.
The MTI should be completed using all available
information-history from patient and care givers, clinical
records as well as other sources, for example, results of
structured evaluations. The inventory is primarily
designed for use in the current episode, for which treat-
ment resistance is being rated for. However, the MTI
may also be used for rating treatment resistance for mul-
tiple episodes. If rating for multiple episodes, multiple
MTIs need to be completed. The MTI lists medications
available in the UK, but can be modified for use in other
countries, by adding the new list of drugs available in
the specific setting or modifying the brand names as ap-
propriate. Preliminary assessment of “pseudo-resistance”
can be made by evaluating treatment adherence, tole-
rability of treatment, and treatment response included in
the MTI. “Pseudo-resistance” refers to an apparent treat-
ment resistance in the face of misdiagnosis, inadequate
treatment because of poor tolerability and poor adhe-
rence. For example, if a person was non-adherent for a
substantial period of the follow-up time or was unable
to tolerate a medication at an acceptable minimum
effective dose, true treatment resistance is unlikely.
For the purposes of the MSM, we recommend using
remission as the desired treatment outcome. Rating of
treatment response can use the MTI response ratings or
standard scale based ratings although we recommend
the latter (Table 4).
Dimension 2: Severity
The MSM was developed using an enhanced ICD-10 se-
verity rating. This rating can be made using an ICD-10
symptom checklist. Equally acceptable would be to use a
DSM 5 checklist. The main advantage of using the ICD/
DSM for severity assessment is its clinical utility. How-
ever, the common approach in research and tertiary care
settings is the use of standard severity rating instru-
ments. Therefore, we recommend using standard instru-
ments such as the HRSD and the QIDS whenever
possible. Ratings for the five severity levels are proposed
(Table 4). We are aware that the presence of even
limited number of symptoms compatible with previous
recommendations of remission would be associated with
impaired functioning and quality of life [62, 64, 65, 91,
102, 103]. Nevertheless, at present, no concrete research
data exists to provide cut-off scores in line with these
recent findings. The only instruments that may allow
clinical judgment about subthreshold symptoms and
remission are the LIFE chart and the CGI. We have
therefore taken the pragmatic approach and restricted
our recommendations to what has been well established
while awaiting further research.
Dimension 3: Duration of depressive episode
The two key questions regarding duration of the depres-
sive episode are: when should the onset of the depressive
episode be dated? And what should the period of remis-
sion be to separate two apparently distinct episodes into
two? In relation to dating onset, we propose provision of
separate options for a new episode and relapse episode.
Table 4 Severity ratings compatible with the MSM for commonly used rating scales
Instrument Clinical status categories based on severity scores Remark
Remission Subthreshold Mild Moderate Severe Very severe
QIDS-C16 0–5 6–10 11–15 16–20 > 20 Remission scores are likely to be too high and include subthreshold
status
QIDS-SR16 0–5 6–10 11–15 16–20 > 20
IDS-C 0–11 12–23 24–36 37–46 > 46
IDS-SR 0–13 14–25 26–38 39–48 > 48
HRSD17 0–7 8–13 14–19 20–25 26–52
MADRS 0–6 7–19 20–34 35–60
CGI 1 2 3 4 5–6 7
PSR 1–2 3 4 5 6 7
Abbreviations: CGI-Clinical Global Impression; HRSD17-Hamilton Rating Scale for Depression (17 item scale); IDS-C-Inventory of Depressive Symptoamtology,
Clinician Rating; IDS-SR-Inventory of Depressive Symptomatology, Self-Report; MADRS-Montgomery-Asberg Depression Rating Scale*; PSR-Psychiatric Status Rating;
QIDS-C-Quick Inventory of Depressive Symptomatology Clinician rated version; QIDS-SR-Quick Inventory of Depressive Symptomatology Self Rated version
Note: Adapted from http://www.ids-qids.org/interpretation.html (accessed on 29 Jan 2016) and the original sources of the instruments except for MADRS [108]
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For first episode, we propose dating the onset to the
time of clear onset of a full episode of illness. For subse-
quent episodes, we propose to date the onset to the time
when prodromal symptoms of relapse have begun. This
distinction is made for the simple pragmatic reason that
we know more about the contribution of subthreshold
symptoms in relapse and maintenance of depressive
episodes. However, relevance of these propositions has
to be tested. The standard duration of remission to
separate two episodes is two months. There is no clear
reason as to why this duration was chosen, other than
the assumption that, in the event of a new episode when
the remission has been under two months, may simply
be a continuation of the initial illness process rather
than emergence of a relapse episode. There is clear un-
certainty regarding duration of remission that heralds
the onset of a more sustained remission. Further
research in this area is warranted.
Three duration categories are recognised in the
MSM. Rating these simply requires a standard clinical
interview (Table 5), which enables accurate dating of
the onset of the treatment-resistant episode. This
should include the period prior to the initiation of the
treatment.
Who should complete the MSM?
In our research and clinical practice at a tertiary centre,
the MSM is completed by research or clinical psychia-
trists and trainee psychiatrists. However, the MSM may
be rated by a trained research nurse or junior research
staff who can complete standard instruments, such as
the HRSD. In research context where multiple users are
likely to be involved, inter-rater agreement needs to be
established.
Discussion
Agreement on the definition of TRD has remained
elusive in four decades. The inability of the recent
Medicare Evidence Development and Coverage Advis-
ory Committee to reach a consensus on defining TRD
confirms the challenge. Nevertheless, treatment
resistance is a vexed concept even in other chronic
conditions. For example, an extensive review by the
US Health Technology Assessment Group looking at
literature spanning nearly 30 years and with the
inclusion of 357 articles, failed to find consensus in
the definition of treatment-resistant epilepsy (TRE)
[104]. TRE was defined in less than a third of the
studies. When a definition was given, it typically in-
cluded the number of failed antiepileptic medications
tried, and in some cases included the adequacy of
dosage, the frequency of seizures and the duration of
illness [104]. The authors also commented that “terms
such as “intractable,” “refractory,” or “treatment-resist-
ant” (were used)1 to describe patients for whom one
or more treatments have failed, (but)† no consensus
exists as to precisely what these terms mean”. The
expert panel then defined treatment-resistance as
“failure of one or more antiepileptic drugs at a
maximum tolerable dose to provide complete seizure
relief”. In line with this consensus definition for RTE,
and evidence that failure of the first antidepressant
may be associated with subsequent reduced respon-
siveness, we have suggested that failure of one treat-
ment should be the threshold for defining TRD. We
thus suggest that failure to respond to the first treat-
ment should count towards defining TRD. We also
suggest that, despite its common usage, the term ‘re-
fractory’ depression is a term that should no longer
be used unless an end stage treatment-resistance is
considered in which psychosurgery is being consid-
ered. The term refractory implies that virtually all
chances of the person responding to treatment are
gone. This proposition is contrary to reports of out-
come studies, which suggest that, despite chronicity,
most patients improve in the longer term with or
without treatment [27, 105–107]. The term “refrac-
tory” may also have unwarranted neuro-physiological
overtone, as in nerve conduction. There is no clear
evidence to support the occurrence of a similar
phenomenon in the treatment of depression. It there-
fore appears that the term “refractory” depression is
at best poorly validated concept and at worst thera-
peutically unhelpful and can potentially encourage
therapeutic nihilism. We suggest to no longer use this
term until firm evidence confirms its validity, or use
it only for a subgroup of patients with an agreed
“end-stage” pattern of resistance.
Treatment-resistance is not an all or none
phenomenon but is rather a continuum, and the prefer-
able representation of treatment resistance would be to
describe the level of treatment-resistance in terms of
various severity grades. Such severity gradation would
be useful as the term TRD itself is non-specific and
generic.
Although remission remains a recommended treat-
ment target, this is not always achievable and should not
be a cause for therapeutic nihilism. Improving symptoms
with antidepressants when the severity scores go down
Table 5 Rating for duration of depressive episode
Duration of depressive episode
Duration Category Duration Rating
Acute < 1 year
Subacute 1 to < 2 years
Chronic 2 years and above
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to the mild and subthreshold range may be even more
challenging and the risk-benefit balance of psychotropic
medications more difficult to determine. In the language
of the BAP guideline for treatment of depression [34],
treatment of treatment-resistant conditions should be
guided by “pragmatism and clinical judgement” based on
“the risk–benefit balance in specific situations rather
than using an arbitrary cut-off. This requires taking into
account an individual’s history and the availability of al-
ternative evidence-based treatments…” Managing
treatment-resistant mental illness is an “art of the pos-
sible”. Systematic follow-up and monitoring of patients
without changing or adding medications may be of
meaningful benefit to patients with treatment-resistant
illness.
Conclusions
The framework and tools of the MSM offer a platform
for shared understanding and replicable research in
TRD. However, further short- and long-term develop-
ment work is required. For example, the definitions of
remission, the threshold for TRD and how previous his-
tory of non-response to treatment should be incorpo-
rated into a staging method is unclear. The potential
role of suicidality as severity indicator may need further
exploration. Most importantly, the treatment implication
of the MSM should be explored. Matching the staging
with recovery goals of patients is another key challenge
that requires further work.
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